FRX Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024.

Detailed results of the vote for the election of directors are set out below:

Name of Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Dr. Khalid Islam	10,100,238	96.45%	371,270	3.54%
Mr. Chris A. Rallis	9,688,517	92.52%	782,991	7.47%
Mr. Marco Brughera	9,801,305	93.59%	670,203	6.40%
Dr. Jodi Cook	8,991,182	85.86%	1,480,326	14.14%
Mr. Rostislav Raykov	9,859,679	94.15%	611,829	5.84%

Shareholders voted 97.96% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 93.87% in favour of the compensation paid to the Company’s named executive officers.

For further information, please contact:

Rosty RaykovChief Executive OfficerFennec Pharmaceuticals Inc.T: (919) 636-5144